HST Global Identifies Global Partner for Panamanian Treatment Facility

HAMPTON, Va.--()--HST Global, Inc. (OTCBB: HSTC) today announced that it has identified a global partner for the possible development of a Clinical Treatment Facility in Panama.

This information, coupled with the recent announcement pertaining to the Ecuadorian Treatment Facility, further signifies HST Global’s commitment to develop Cancer Treatment Centers worldwide. As previously stated, HST Global is relying on international markets to reach a worldwide audience. The Company is continually being presented with opportunities to bring its integrative science-based cancer treatment protocols to a global population.

Mr. Ron Howell, CEO and President of HST Global, Inc., stated, “At HST, we continue to take advantage of the relationships we have groomed over the past year. The fact we have partners that are familiar with the demographic idiosyncrasies, economic conditions and political climate of a particular region is invaluable during the initial stages of developing a facility. Through this partnership, we will be able to exploit this indigenous knowledge as well as leverage and align our resources in an effort to develop our Panamanian Treatment Facility.”

Wes Tate, CFO, stated “I am amazed with the global opportunities that we continue to receive. This has enabled us to strengthen our position and move forward with our international plan of expansion into Ecuador and Panama. This ability is a testament to the team that has been assembled at HST and the relationships that have been established over the past few months. We continue to enhance shareholder value through the implementation of our global growth strategy.”

About HST Global, Inc.

HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.

HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

Contacts

HST Global, Inc.
Investor Relations
David Nesbitt, 757-766-6100
ir@hstglobal.com
www.hstglobal.com

Contacts

HST Global, Inc.
Investor Relations
David Nesbitt, 757-766-6100
ir@hstglobal.com
www.hstglobal.com